Financial Survey: Alumis (ALMS) versus Its Rivals

Alumis (NASDAQ:ALMS) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its competitors? We will compare Alumis to related companies based on the strength of its dividends, earnings, valuation, profitability, risk, analyst recommendations and institutional ownership.

Risk & Volatility

Alumis has a beta of -1.87, suggesting that its share price is 287% less volatile than the S&P 500. Comparatively, Alumis’ competitors have a beta of 0.98, suggesting that their average share price is 2% less volatile than the S&P 500.

Institutional and Insider Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 40.7% of Alumis shares are owned by insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Alumis and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1	0	6	0	2.71
Alumis Competitors	6098	12292	37816	1183	2.59

Alumis presently has a consensus target price of $19.20, suggesting a potential upside of 72.66%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 50.86%. Given Alumis’ stronger consensus rating and higher possible upside, equities analysts clearly believe Alumis is more favorable than its competitors.

Valuation and Earnings

This table compares Alumis and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alumis	N/A	-$294.23 million	-2.75
Alumis Competitors	$938.51 million	-$41.18 million	11.11

Alumis’ competitors have higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Alumis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alumis	N/A	-121.25%	-92.54%
Alumis Competitors	-906.16%	-572.37%	-29.72%

Summary

Alumis competitors beat Alumis on 7 of the 13 factors compared.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.